Let’s go through some study results
TREMFYA® has been clinically studied and proven effective at helping patients with moderate to severe plaque psoriasis achieve clearer skin and fewer symptoms.
See photos below
90% CLEARER SKIN AT 16 WEEKS
In clinical studies, at 16 weeks, at least 7 out of 10 patients saw at least 90% clearer skin.
100% CLEARER SKIN AT 16 WEEKS
In one clinical study, 5 out of 10 patients saw completely clear skin at 16 weeks.
IMPROVED SYMPTOMS AT 16 WEEKS
In clinical studies, at 16 weeks, patients had improvements in symptoms of plaque psoriasis including itching, burning, pain, stinging, and skin tightness.
CLEAR OR ALMOST CLEAR SCALP AT 16 WEEKS
In clinical studies, at week 16, 4 out of 5 people with scalp psoriasis were rated clear or almost clear of their scalp psoriasis.
90% CLEARER SKIN ACROSS ALL SKIN TONES
In another study across all skin tones,* nearly 6 out of 10 patients saw 90% clearer skin at 16 weeks. Results may vary.
*Refers to a dermatology skin tone scale.
In a group of patients with moderate to severe scalp psoriasis, 6 out of 10 patients had at least 90% scalp clearance with nearly all of them 100% clear at 16 weeks. Results may vary.
90% CLEARER SKIN AT 48 WEEKS
In a clinical study, nearly 9 out of 10 people who saw 90% clearer skin at 28 weeks continued to see 90% clearer skin at 48 weeks.
90% CLEARER SKIN AT 5 YEARS
In a study, nearly 7 out of 10 patients with 90% clearer skin at 16 weeks were still clearer at 5 years.
At 1 year and thereafter, patients and healthcare providers knew that TREMFYA® was being used. This may have increased results. Results may vary.
CLEAR OR ALMOST CLEAR SKIN IN LOW-BSA MODERATE PLAQUE PSORIASIS AND HIGH-IMPACT AREAS*
In another study, at least 7 out of 10 patients were rated as clear or almost clear of their psoriasis at 16 weeks. Results may vary.
*High-impact areas have more sensitive skin and can be highly visible, like the face, scalp, skin folds, and genitals. A unique study with TREMFYA® showed that clearer skin is possible in patients with low body surface area (BSA) (2%-15%) moderate plaque psoriasis and plaques in these high-impact areas.
Individual results may vary.
Not everybody’s plaque psoriasis looks the same.
Watch the video to see how TREMFYA®
sees skin differently.
Before & After TREMFYA® Across All Skin Tones
See below for real patient photos before and after TREMFYA® treatment from the first study of its kind to include all skin tones.*
*Refers to a dermatology skin tone scale.
Photos are of real patients with moderate to severe plaque psoriasis who received a single dose of TREMFYA® 100 mg at weeks 0 and 4, and then every 8 weeks. Individual results may vary.
Identifies as African (Black)
Before
TREMFYA®
After 3 doses
WEEK 16
Back
Actual patient
Identifies as Caribbean (Black)
Before
TREMFYA®
After 3 doses
WEEK 16
Back
Actual patient
Identifies as South American (Hispanic/Latino)
Before
TREMFYA®
After 3 doses
WEEK 16
Legs
Actual patient
Identifies as Mexican (Hispanic/Latino)
Before
TREMFYA®
After 3 doses
WEEK 16
Arm
Actual patient
Identifies as Black
Before
TREMFYA®
After 3 doses
WEEK 16
Scalp
Actual patient
Identifies as Caribbean (Black)
Before
TREMFYA®
After 3 doses
WEEK 16
Chest
Actual patient
Identifies as Mexican (Hispanic/Latino)
Before
TREMFYA®
After 3 doses
WEEK 16
Leg
Actual patient
Identifies as Mexican (Hispanic/Latino)
Before
TREMFYA®
After 3 doses
WEEK 16
Arm
Actual patient
Identifies as South Asian (Asian)
Before
TREMFYA®
After 3 doses
WEEK 16
Back
Actual patient
Photos are of real patients with moderate to severe plaque psoriasis who received a single dose of TREMFYA® 100 mg at weeks 0 and 4, and then every 8 weeks. Individual results may vary.
Identifies as South Asian (Asian)
Before
TREMFYA®
After 3 doses
WEEK 16
Back
Actual patient
Photos are of real patients with moderate to severe plaque psoriasis who received a single dose of TREMFYA® 100 mg at weeks 0 and 4, and then every 8 weeks. Individual results may vary.
Identifies as African (Black)
Before
TREMFYA®
After 3 doses
WEEK 16
Back
Actual patient
Identifies as Black
Before
TREMFYA®
After 3 doses
WEEK 16
Scalp
Actual patient
Identifies as Caribbean (Black)
Before
TREMFYA®
After 3 doses
WEEK 16
Chest
Actual patient
Identifies as Caribbean (Black)
Before
TREMFYA®
After 3 doses
WEEK 16
Back
Actual patient
Photos are of real patients with moderate to severe plaque psoriasis who received a single dose of TREMFYA® 100 mg at weeks 0 and 4, and then every 8 weeks. Individual results may vary.
Identifies as Mexican (Hispanic/Latino)
Before
TREMFYA®
After 3 doses
WEEK 16
Leg
Actual patient
Identifies as Mexican (Hispanic/Latino)
Before
TREMFYA®
After 3 doses
WEEK 16
Arm
Actual patient
Identifies as South American (Hispanic/Latino)
Before
TREMFYA®
After 3 doses
WEEK 16
Legs
Actual patient
Identifies as Mexican (Hispanic/Latino)
Before
TREMFYA®
After 3 doses
WEEK 16
Arm
Actual patient
First-of-its-kind
Minority representation has been less than 30% in plaque psoriasis biologic treatment trials. That’s why we launched a first-of-its-kind study specifically across all skin tones.*
*Refers to a dermatology skin tone scale.
Across skin tones
Psoriasis can look different across skin tones, which is something that is often overlooked when considering treatment.
You’re always included
We’re committed to conducting innovative clinical research that includes patients with different skin tones.
Before & After TREMFYA® in Low-BSA Moderate Plaque Psoriasis and High-Impact Areas
See below for before and after photos of real patients with low body surface area (BSA) (2%-15%) moderate plaque psoriasis and plaques in high-impact areas.
Photos are of real patients who received TREMFYA® 100 mg at weeks 0 and 4, and then every 8 weeks.
Individual results may vary.
Scalp
Before
TREMFYA®
After 3 doses
WEEK 16
Actual patient
Scalp
Before
TREMFYA®
After 3 doses
WEEK 16
Actual patient
Skin folds
Before
TREMFYA®
After 3 doses
WEEK 16
Actual patient
Skin folds
Before
TREMFYA®
After 3 doses
WEEK 16
Actual patient
High-impact site results at 16 weeks with at least moderate severity
Scalp
At least 7 out of 10 patients on TREMFYA® were rated clear or almost clear of their scalp psoriasis.
Face
At least 8 out of 10 patients on TREMFYA® were rated clear or almost clear of their facial psoriasis.
Genitals
At least 7 out of 10 patients on TREMFYA® were rated clear or almost clear of their genital psoriasis.
Skin folds
At least 8 out of 10 patients on TREMFYA® were rated clear or almost clear of psoriasis in skin fold areas.
TREMFYA® is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.
Psoriatic arthritis is a chronic, or long-term, disease. It affects about 30% of people with psoriasis. While the exact cause is unknown, when you have psoriatic arthritis, your immune system attacks healthy tissues like the skin and joints.
Click the button below to learn more about how TREMFYA® could help treat adults with active psoriatic arthritis.
Get your own English or Spanish brochure and discussion guide
Doctor Discussion Guide
Take this guide with you to your next dermatologist appointment. It’s designed to help patients across all skin tones have an open and honest conversation about their plaque psoriasis.
Guía de Discusión del Médico
Lleve esta guía con usted a su próxima cita con el dermatólogo. Está diseñada para ayudar a los pacientes de todos los tonos de piel a tener una conversación abierta y sincera sobre su psoriasis en placas.
TREMFYA® Safety Information
Ask your doctor about the benefits and risks of TREMFYA®. Prescription medications, including TREMFYA®, have possible risks involved with treatment, so it’s important to discuss them with your doctor.
TREMFYA® may cause serious side effects, including:
- Serious allergic reactions. Stop using TREMFYA® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
- fainting, dizziness, feeling lightheaded (low blood pressure)
- swelling of your face, eyelids, lips, mouth, tongue or throat
- trouble breathing or throat tightness
- chest tightness
- skin rash, hives
- itching
- fainting, dizziness, feeling lightheaded
(low blood pressure) - swelling of your face, eyelids, lips,
mouth, tongue or throat
- trouble breathing or throat tightness
- chest tightness
- skin rash, hives
- itching
- Infections. TREMFYA® is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA® and may treat you for TB before you begin treatment with TREMFYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA®.
Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
- fever, sweats, or chills
- cough
- shortness of breath
- blood in your phlegm (mucus)
- muscle aches
- warm, red, or painful skin or sores on your body different from your psoriasis
- weight loss
- diarrhea or stomach pain
- burning when you urinate or urinating more often than normal
- fever, sweats, or chills
- cough
- shortness of breath
- blood in your phlegm (mucus)
- muscle aches
- warm, red, or painful skin or
sores on your body different
from your psoriasis
- weight loss
- diarrhea or stomach pain
- burning when you urinate or
urinating more often than
normal
These are not all the possible side effects of TREMFYA®.
Please read the Important Safety Information located at the bottom of the screen and the Medication Guide for TREMFYA® to learn more about these and other risks for TREMFYA®. Discuss any questions you have with your doctor.
TREMFYA® may cause serious side effects including:
- See “What is the most important information I should know about TREMFYA®?”The most common side effects of TREMFYA® include:
- upper respiratory infections
- joint pain (arthralgia)
- fungal skin infections
- headache
- diarrhea
- herpes simplex infections
- injection site reactions
- stomach flu (gastroenteritis)
- bronchitis
These are not all the possible side effects of TREMFYA®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
WHAT IS TREMFYA® (guselkumab)?
TREMFYA® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).
TREMFYA® is a prescription medicine used to treat adults with active psoriatic arthritis.
TREMFYA® is a prescription medicine used to treat adults with moderately to severely active ulcerative colitis.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about TREMFYA®?
TREMFYA® is a prescription medicine that may cause serious side effects, including:
- Serious Allergic Reactions. Stop using TREMFYA® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
|
|
- Infections. TREMFYA® may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA® and may treat you for TB before you begin treatment with TREMFYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA®.
Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
|
|
Do not take TREMFYA® if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA®.
Before using TREMFYA®, tell your healthcare provider about all of your medical conditions, including if you:
- have any of the conditions or symptoms listed in the section “What is the most important information I should know about TREMFYA®?”
- have an infection that does not go away or that keeps coming back.
- have TB or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA®.
- are pregnant or plan to become pregnant. It is not known if TREMFYA® can harm your unborn baby.
Pregnancy Registry: If you become pregnant during treatment with TREMFYA®, talk to your healthcare provider about registering in the pregnancy exposure registry for TREMFYA®. You can enroll by visiting www.mothertobaby.org/ongoing-study/tremfya-guselkumab, by calling 1-877-311-8972, or emailing MotherToBaby@health.ucsd.edu. The purpose of this registry is to collect information about the safety of TREMFYA® during pregnancy.
- are breastfeeding or plan to breastfeed. It is not known if TREMFYA® passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of TREMFYA®?
TREMFYA® may cause serious side effects. See “What is the most important information I should know about TREMFYA®?”
The most common side effects of TREMFYA® include: respiratory tract infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, and bronchitis.
These are not all the possible side effects of TREMFYA®. Call your doctor for medical advice about side effects.
Use TREMFYA® exactly as your healthcare provider tells you to use it.
Please read the full Prescribing Information, including Medication Guide, for TREMFYA® and discuss any questions that you have with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Dosage Forms and Strengths: TREMFYA® is available in a 100 mg/mL prefilled syringe and One-Press patient-controlled injector for subcutaneous injection, a 200 mg/2 mL prefilled syringe and prefilled pen (TREMFYA® PEN) for subcutaneous injection, and a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.
cp-82626v7
WHAT IS TREMFYA® (guselkumab)?
TREMFYA® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).
TREMFYA® is a prescription medicine used to treat adults with active psoriatic arthritis.
TREMFYA® is a prescription medicine used to treat adults with moderately to severely active ulcerative colitis.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about TREMFYA®?
TREMFYA® is a prescription medicine that may cause serious side effects, including:
- Serious Allergic Reactions. Stop using TREMFYA® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
|
|
- Infections. TREMFYA® may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA® and may treat you for TB before you begin treatment with TREMFYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA®.
Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
|
|
Do not take TREMFYA® if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA®.
Before using TREMFYA®, tell your healthcare provider about all of your medical conditions, including if you:
- have any of the conditions or symptoms listed in the section “What is the most important information I should know about TREMFYA®?”
- have an infection that does not go away or that keeps coming back.
- have TB or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA®.
- are pregnant or plan to become pregnant. It is not known if TREMFYA® can harm your unborn baby.
Pregnancy Registry: If you become pregnant during treatment with TREMFYA®, talk to your healthcare provider about registering in the pregnancy exposure registry for TREMFYA®. You can enroll by visiting www.mothertobaby.org/ongoing-study/tremfya-guselkumab, by calling 1-877-311-8972, or emailing MotherToBaby@health.ucsd.edu. The purpose of this registry is to collect information about the safety of TREMFYA® during pregnancy.
- are breastfeeding or plan to breastfeed. It is not known if TREMFYA® passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of TREMFYA®?
TREMFYA® may cause serious side effects. See “What is the most important information I should know about TREMFYA®?”
The most common side effects of TREMFYA® include: respiratory tract infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, and bronchitis.
These are not all the possible side effects of TREMFYA®. Call your doctor for medical advice about side effects.
Use TREMFYA® exactly as your healthcare provider tells you to use it.
Please read the full Prescribing Information, including Medication Guide, for TREMFYA® and discuss any questions that you have with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Dosage Forms and Strengths: TREMFYA® is available in a 100 mg/mL prefilled syringe and One-Press patient-controlled injector for subcutaneous injection, a 200 mg/2 mL prefilled syringe and prefilled pen (TREMFYA® PEN) for subcutaneous injection, and a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.
cp-82626v7